Skip to main content
Sign In
 

Open and Enrolling Studies


 

ACTG A5279: Phase III clinical trial of ultra-short course Rifapentine/Isoniazid for the prevention of active tuberculosis in HIV-infected individuals with latent tuberculosis infection. 

 

ACTG A5308: A prospective, single-arm, open-label study to evaluate the effect of fixed-dose Emtricitabine/Rilpivirine/Tenofovir Disproxil Fumarate on T-cell activation, absolute CD4+ T-cell count, inflammatory biomarkers and viral reservoir in treatment-naive HIV-1 controllers.

 

ACTG A5314: Effect of reducing inflammation with low dose methotrexate on inflammatory markers and endothelial function in treated and suppressed HIV infection.

 

ACTG A5315: A phase I/II study of single dose romidepsin in HIV infected adults with suppressed viremia on antiretroviral therapy to assess safety, tolerability and activation of HIV-1 expression.

 

ACTG A5317: Effects of Telmisartan on fibrotic, inflammatory, and metabolic contributors to end-organ disease in HIV-infected patients well controlled on antiretroviral therapy.

 

ACTG A5320: Viral hepatitis C infection long-term cohort study (H-HICS)

 

ACTG A5321: Decay of HIV-1 reservoirs in subjects on long-term antiretroviral therapy: the ACTG HIV reservoirs cohort (AHRC) study

 

ACTG A5322: Long-term follow-up of older HIV-infected adults in the ACTG: addressing issues of aging, HIV infection and inflammation

 

ACTG A5128: Plan for obtaining informed consent to use stored human biological materials for currently unspecified analyses.

 

COPD and HIV: Immunosuppressive effects of smoking and HIV-1 on the development of lung disease